~Consilium is ARM’s retained strategic communications advisor in Europe and official media partner for the meeting~
London, 23 April 2019, Consilium Strategic Communications, a global leader in strategic healthcare communications and investor relations, is pleased to be supporting the Alliance of Regenerative Medicine (ARM) as its official Media Partner at the inaugural Cell & Gene Meeting on the Mediterranean, taking place from 23-25 April in Barcelona, Spain.
ARM is an international multi-stakeholder advocacy organization that promotes legislative, regulatory, and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. The event, modelled on ARM’s highly successful Cell & Gene Meeting on the Mesa, brings together the entire cell and gene therapy community from Europe and beyond. The program, which is expected to attract more than 250 attendees, will feature expert-led panels, extensive one-on-one partnering capabilities, exclusive networking opportunities, and 50+ dedicated presentations by the leading publicly traded and privately held companies in the space. Panels and discussions will focus on some of the key topics and issues facing the sector, including manufacturing, pricing and reimbursement, and the scientific, clinical, and regulatory landscape going forward.
“We are pleased to be ARM’s retained strategic communications advisor in Europe and official media partner at the inaugural Meeting on the Mediterranean in Barcelona. ARM has produced a fantastic program with many high quality, expert speakers. We are looking forward to the meeting and to welcoming the industry, regulators, investors and media, that are attending.”
Chris Gardner
Partner of Consilium Strategic Communications
“We are excited to be hosting our very first 2019 Cell & Gene Meeting on the Mediterranean starting today in Barcelona and are very grateful for the support Consilium has provided. Europe plays a significant role across all areas of cell and gene therapies and this is a fantastic opportunity to bring leading experts, companies, industry bodies and regulators together to discuss these potentially transformative therapies and how we can work together to make them available to patients.”
Janet Lambert
CEO of ARM
For members of the media interested in speaking to attendees, please contact Matthew Neal / Sarah Wilson on ARM@consilium-comms.com
Confirmed speakers include:
- Guido Rasi, Director General, European Medicines Agency (EMA)
- Keith Thompson, CEO, Cell and Gene Therapy Catapult
- Matthew Durdy, Chief Business Officer, Cell and Gene Therapy Catapult
- Dan Faga, Chief Business Officer, Spark Therapeutics
- Alison Finger, Chief Commercial Officer, bluebird bio
- Claire Foreman, Head of Acute Programs, National Health Service
- Owen Marks, Country Lead, Rare Diseases, Pfizer
- Pascal Touchon, SVP, Global Head of Cell and Gene Europe, Novartis
- Luca Alberici, Ph.D., Chief Business Officer, MolMed
- Etienne Jousseaume, Head of Market Access, Cell and Gene Europe, Novartis
- Jason Meyenburg, Chief Commercial Officer, Orchard Therapeutics
- Usman Azam, President and CEO, Tmunity Therapeutics
- Thomas Fellner, Ph.D., Head of Cell and Gene Therapy, Lonza
- Joseph Tarnowski, Ph.D., SVP, Cell and Gene Therapy Platforms, Medicinal Science and Technology, R&D, GSK
- Matthew Patterson, Chairman and CEO, Audentes Therapeutics; Chairman, Alliance for Regenerative Medicine
- Amy DuRoss, Co-Founder and CEO, Vineti
- Sven Kili, M.D., Principal, Sven Kili Consulting
- Christopher Vann, Chief Operating Officer, Autolus Therapeutics
- Rogerio Vivaldi, M.D., President and CEO, Sigilon Therapeutics
- Ian Hudson, M.D., Chief Executive, Medicines and Healthcare Products Regulatory Agency
- Katsuaki Ura, Deputy Director, Office of International Regulatory Affairs, Pharmaceutical Safety and Environmental Health Bureau, Ministry of Health, Labour and Welfare
2019 presenting companies include: 3Scan; Adaptimmune; AGTC; Akron Biotech; Andalusian Initiative for Advanced Therapies; Aspect Biosystems; Audentes Therapeutics; Avectas; Axovant Gene Therapies; Biostage; bluebird bio; BlueRock Therapeutics; B-MoGen Biotechnologies; Bone Therapeutics; Caribou Biosciences; CEVEC Pharmaceuticals; Chimeric Therapeutics; Cryoport; Cynata Therapeutics; DiscGenics; FloDesign Sonics; FUJIFILM Cellular Dynamics; Genethon; Giner Life Sciences; Healios; Invitrx Therapeutics; Iovance Biotherapeutics; Kiadis Pharma; LogicBio Therapeutics; MaxCyte; MolMed; NAVAN Technologies; Novadip Biosciences; Orchard Therapeutics; Organovo; ORIG3N; Oxford Biomedica; panCELLa; PDC*line Pharma; PolarityTE; Promethera Biosciences; REGENXBIO; ReNeuron; Rexgenero; Sangamo Therapeutics; Sigilon Therapeutics; Spark Therapeutics; Terumo BCT; TikoMed; T-knife; Tmunity Therapeutics; uniQure; VERIGRAFT; Vivet Therapeutics; and Zelluna Immunotherapy.
For full details on the agenda, access to the live webcast or further information about the event, please visit www.meetingonthemed.com
